Article
Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion
Fecha
2011Registro en:
10.1089/met.2012.0183
Autor
Gonzalez-Ortiz, M.
Martinez-Abundis, E.
Robles-Cervantes, J.A.
Ramos-Zavala, M.G.
Institución
Resumen
Background: The aim of this study was to evaluate the effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome. Methods: An uncontrolled, open clinical study was carried out in 10 patients with metabolic syndrome and without pharmacological treatment. Patients received exenatide (5 ?g) subcutaneously twice daily for 1 month. Before and after the intervention, metabolic profile and phases of insulin secretion and insulin sensitivity were estimated. To assess insulin secretion and sensitivity, the hyperglycemic-hyperinsulinemic clamp technique was performed. Computed tomography was performed to evaluate both subcutaneous and visceral fat. The Wilcoxon signed-rank test and Mann-Whitney U-test were used for statistical analyses. Results: Weight, body mass index, waist circumference, and systolic blood pressure were decreased by exenatide. Subcutaneous fat deposition decreased by 4.4% compared to the basal value. There were significant decreases in total cholesterol and low-density lipoprotein cholesterol, as well as an increment in the first phase of insulin secretion after the intervention. Conclusion: One-month administration of exenatide significantly decreased subcutaneous fat deposition by 4.4%, improving the metabolic profile in patients with metabolic syndrome. " Copyright 2011, Mary Ann Liebert, Inc.",,,,,,"10.1089/met.2010.0025",,,"http://hdl.handle.net/20.500.12104/40936","http://www.scopus.com/inward/record.url?eid=2-s2.0-79955515747&partnerID=40&md5=dfb6fc9fdf83e421059a40fa2ed6925a http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=20874425",,,,,,"1",,"Metabolic Syndrome and Related Disorders",,"31 34",,"9",,"Scopus WOS MEDLINE",,,,,,"Index Medicus;Adipose Tissue/de [Drug Effects];Adipose Tissue/me [Metabolism];Adult;Body Fat Distribution;Drug Administration Schedule;Female;Humans;Hypoglycemic Agents/ad [Administration & Dosage];Hypoglycemic Agents/pd [Pharmacology];Injections, Subcutaneous;Lipids/bl [Blood];Male;Metabolic Syndrome X/dt [Drug Therapy];Metabolic Syndrome X/me [Metabolism];Metabolome/de [Drug Effects];Peptides/ad [Administration & Dosage];Peptides/pd [Pharmacology];Venoms/ad [Administration & Dosage];Venoms/pd [Pharmacology];Young Adult",,,,,,"Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome",,"Article"
"42690","123456789/35008",,"Pérez-Rubio, K.G., Physiology Department, Health Science University Center, University of Guadalajara, Montes Urales 1409, 44340 Guadalajara, Mexico; González-Ortiz, M., Physiology Department, Health Science University Center, University of Guadalajara, Montes Urales 1409, 44340 Guadalajara, Mexico, Medical Research Unit in Clinical Epidemiology, Mexican Institute of Social Security, Specialties Hospital, Guadalajara, Mexico; Martínez-Abundis, E., Physiology Department, Health Science University Center, University of Guadalajara, Montes Urales 1409, 44340 Guadalajara, Mexico; Robles-Cervantes, J.A., Medical Research Unit in Clinical Epidemiology, Mexican Institute of Social Security, Specialties Hospital, Guadalajara, Mexico; Espinel-Bermúdez, M.C., Medical Research Unit in Clinical Epidemiology, Mexican Institute of Social Security, Specialties Hospital, Guadalajara, Mexico",,"Perez-Rubio, K.G. Gonzalez-Ortiz, M. Martinez-Abundis, E. Robles-Cervantes, J.A. Espinel-Bermudez, M.C.",,"2013",,"Background: The aim of this study was to evaluate the effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients with a diagnosis of metabolic syndrome. Glucose and insulin levels after a dextrose load were measured. Triglycerides and high-density lipoprotein cholesterol concentrations at baseline were also measured. Twelve patients received berberine hydrochloride (500 mg) three times daily before meals for 3 months. The remaining 12 patients received placebo. Area under the curve (AUC) of glucose and insulin, total insulin secretion, first-phase of insulin secretion, and insulin sensitivity were assessed. Results: After berberine administration, patients had a remission of 36% (P=0.037) in the presence of metabolic syndrome and a significant decrease in waist circumference in females (106 4 vs. 103 3 cm, P<0.05), systolic blood pressure (SBP) (123 7 vs. 115 9 mmHg, P<0.01), triglycerides (2.4 0.7 vs. 1.4 0.5 mmol/L, P<0.01), area under the curve (AUC) of glucose (1182.1 253.6 vs. 1069.5 172.4 mmol/l, P<0.05), AUC of insulin (92,056 72,148 vs. 67,407 46,441 pmol/L, P<0.01), and insulinogenic index (0.78 0.69 vs. 0.62 0.46, P<0.05), as well as an increase in the Matsuda index (2.1 1.0 vs. 3.1 1.6, P<0.01). Conclusions: Administration of berberine leads to remission of metabolic syndrome and decreases in waist circumference, SBP, triglycerides, and total insulin secretion, with an increase in insulin sensitivity. " Mary Ann Liebert, Inc.